TriNetX adds medical center with 1,000 ongoing trials to its network

By Vassia Barba

- Last updated on GMT

(Image: Getty/torwai)
(Image: Getty/torwai)

Related tags TriNetX Clinical trial Clinical research research network

University of Rochester Medical Center joined the global health research network aiming to ‘expand its access to advanced clinical trials’, TriNetX announced.

With a 846-bed Strong Memorial Hospital, Eastman Institute for Oral Health, and the University of Medicine and Dentistry, Medical Faculty Group, and School of Nursing, the URMC currently has over a 3,000 person research staff working on over 1,000 ongoing clinical trials related to cancer, heart disease, Parkinson's and pandemic influenza, among other diseases.

Since April 2019, the sponsors who wish to discuss new clinical trials can reach URMC through Trial Connect, a TriNetX service, and they are directly connected to the center's investigators.

Professor of Medicine and Public Health Sciences at UMRC, Martin Zand, said that TriNetX has presented clinical trials that ‘exactly matched’ the center’s primary areas of therapeutic interest.

Patricia Ames, director of URMC's Office of Clinical Research told us that the academic medical center already receives 'multiple queries per week'.

"So far, we are considering opening studies that originated from the TriNetX platform in dentistry, ophthalmology and neurology indications,"​ Ames added.

Global expansion

TriNetX network of health care organization partnerships spans across 23 countries and thousands of sites. Data providers within the network cover 99% of US health plays and represent over 300 million patients.

The network has been used, according to the company, to analyze over 16,000 protocols and has presented over 4,190 clinical trial opportunities to its health care organization partners.

TriNetX has been expanding globally during the past few months. On March, it closed a series D financing round, receiving a total fund of $102m​. Its customer base includes 29 pharmaceutical companies, such as Pfizer​, Novartis and Sanofi​.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers